2b:,MRI

Jiwon Oh1, Robert J Fox2, Douglas Lorne Arnold3

  • 1Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto.

Neurology open access
|February 20, 2026
PubMed
概括

托莱布鲁丁尼,一种口服布鲁顿的氨酸激酶 (BTK) 抑制剂,在两年内在多发性硬化症 (MS) 患者中表现出可接受的安全性和持续的疗效. 该药物对MRI病变和复发率表现出持久的影响,支持其作为疾病修饰疗法的潜力.